secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenland Mines Ltd (GRML)
CIK:        0001907223
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001213900-25-075016
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Klotho Neurosciences signs $250K manufacturing deal with AAVnerGene for KLTO-202 gene therapy
--------------------------------------------------------------------------------

- Initial fees of $250,000; additional fees tied to clinical trial stages plus 2% royalty on product revenue.
- Agreement covers manufacturing and development of KLTO-202 using AAVnerGene's AAVone platform technology.
- AAVnerGene's ATHENA tissue-targeting system aims to avoid liver homing and reduce inflammatory side effects.
- CEO states partnership expected to lower cost, increase purity, and accelerate time to clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025075016/0001213900-25-075016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025075016/ea0252863-8k_klotho.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer